Hui Han, Dan Zhao, Xinru Fang, Wenming Yang, Mengli Wang, Qianzhuo Liu, Luyao Wang, Zhihui Ji, Juan Zhang, Zhifeng Hou, Lei Hua, Yu Wang, Limin Wu
BACKGROUND: Wilson's disease (WD) is a rare hepatic and neurological disorder,23003132cwhich can dramatically worsen by traumatic injuries, surgeries, and infections. No studies have reported safety data of severe acute respiratory syndrome coronavirus 2 (People's Republic of ChinaSARS-CoV-2) vaccination in WD patients. We aimed to investigate the SARS-CoV-2 vaccination status and post-vaccination adverse events in WD patients. METHODS: This is a multicenter, retrospective, observational study...
November 27, 2023: Expert Review of Vaccines
Rui Lin, Hui Jin, Xin Fu
OBJECTIVES: Despite their use, differences in human papillomavirus (HPV) vaccine efficacies remain uncertain. This study assesses efficacy differences among bivalent, quadrivalent, and nine-valent HPV (2vHPV, 4vHPV, and 9vHPV) vaccines. METHODS: PubMed, Web of Science, Embase, and the Cochrane Library were searched for randomized controlled trials comparing HPV vaccine efficacy against persistent infection (≥6 months) and cervical intraepithelial neoplasia grade 2 or worse (CIN2+)...
November 22, 2023: Expert Review of Vaccines
Marco Del Riccio, Sara Boccalini, Claudia Cosma, Gabriele Vaccaro, Benedetta Bonito, Beatrice Zanella, Cristina Salvati, Duccio Giorgetti, Lisa Rigon, Massimiliano Alberto Biamonte, Matteo Monami, Paolo Bonanni, Angela Bechini
INTRODUCTION: Diabetic patients are at ahigher risk of getting pneumococcal disease and are therefore recommended toget vaccinated. The aim of our systematic review is the retrieval and analysisof all available evidence on the effect of pneumococcal vaccination on the riskof hospitalization and death in adult patients with diabetes. RESEARCH DESIGN AND METHODS: MEDLINEand EMBASE were searched from inception until January 2023. We included allstudies investigating whether pneumococcal vaccination reduces the risk ofdying or being hospitalized in diabetic patients...
November 22, 2023: Expert Review of Vaccines
Alberto Cagigi, Bruno Douradinha
INTRODUCTION: After receiving emergency approval during the COVID-19 pandemic, mRNA vaccines have taken center stage in the quest to enhance future vaccination strategies for both infectious diseases and cancer. Indeed, they have significantly overshadowed another facet of genetic vaccination, specifically DNA vaccines. Nevertheless, it is important to acknowledge that both types of genetic vaccines have distinct advantages and disadvantages that set them apart from each other. AREAS COVERED: In this work, we delve extensively into the history of genetic vaccines, their mechanisms of action, their strengths, and limitations, and ultimately highlight ongoing research in key areas for potential enhancement of both DNA and mRNA vaccines...
November 8, 2023: Expert Review of Vaccines
Florence Boisnard, Christine Manson, Laurence Serradell, Denis Macina
INTRODUCTION: Hexaxim® is fully liquid, hexavalent, combination vaccine that provides immunization against diphtheria, tetanus, pertussis (whooping cough), polio, hepatitis B, and invasive diseases caused by Haemophilus influenzae type b. Combination vaccines such as Hexaxim reduce the number of injections needed, improving both vaccination compliance and operational efficiency. AREAS COVERED: Safety and immunogenicity data were reviewed from > 25 clinical trials involving approximately 7200 infants/toddlers, identified using PubMed searches to April 2023...
November 7, 2023: Expert Review of Vaccines
Jéssica L Chechi, Felipe A C da Costa, Julia M Figueiredo, Cássia M de Souza, Alessandro F Valdez, Daniel Zamith-Miranda, Aline C Camara, Carlos P Taborda, Joshua D Nosanchuk
INTRODUCTION: Fungal infections are caused by a broad range of pathogenic fungi that are found worldwide with different geographic distributions, incidences and mortality rates. Considering that there are relatively few approved medications available for combating fungal diseases and no vaccine formulation commercially available, multiple groups are searching for new antifungal drugs, examining drugs for repurposing and developing antifungal vaccines, in order to control deaths, sequels and the spread of these complex infections...
November 7, 2023: Expert Review of Vaccines
Claire E Mellott, Rafal Jaworski, Justin Carrico, Sandra E Talbird, Iwona Dobrowolska, Dominik Golicki, Goran Bencina, Micah Clinkscales, Eugenia Karamousouli, Amanda L Eiden, Ugne Sabale
BACKGROUND: This study aimed to evaluate the epidemiological impact and return on investment of the pediatric immunization program (PIP) in Poland from the healthcare-sector and societal perspectives. RESEARCH DESIGN AND METHODS: A health-economic model was developed focusing on the 9 vaccines, targeting 11 pathogens, recommended by public health authorities for children aged 0-6 years in Poland. The 2019 birth cohort (388,178) was followed over their lifetime, with the model estimating discounted health outcomes, life-years gained, quality-adjusted life-years, and direct and indirect costs with and without the PIP based on current and pre-vaccine - era disease incidence estimates, respectively...
November 1, 2023: Expert Review of Vaccines
Charlotte Sorieul, Marta Dolce, Maria Rosaria Romano, Jeroen Codée, Roberto Adamo
INTRODUCTION: Antimicrobial resistance (AMR) is responsible for the death of millions worldwide and stands as a major threat to our healthcare systems, which are heavily reliant on antibiotics to fight bacterial infections. The development of vaccines against the main pathogens involved is urgently required as prevention remains essential against the rise of AMR. AREAS COVERED: A systematic research review was conducted on MEDLINE database focusing on the six AMR pathogens defined as ESPAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Escherichia coli), which are considered critical or high priority pathogens by the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC)...
October 30, 2023: Expert Review of Vaccines
Felicitas Kühne, Katharina Achtert, Franziska Püschner, Dominika Urbanski-Rini, Juliane Schiller, Ernestine Mahar, Josephine Friedrich, Mark Atwood, Ralf Sprenger, Jeffrey Vietri, Christof von Eiff, Christian Theilacker
OBJECTIVES: Despite national recommendations for use ofpneumococcal vaccines, rates of community-acquired pneumonia (CAP) and invasivepneumococcal disease (IPD) remain high in Germany. New pneumococcal conjugatevaccines (PCVs) with expanded coverage have the potential to reduce thepneumococcal disease burden among adults. METHODS: Using a Markov model, we evaluated the lifetimeoutcomes/costs comparing 20-valent PCV (PCV20) with standard of care (SC)vaccination for prevention of CAP and IPD among adults aged ≥60 years and at-riskadults aged 18-59 years in Germany...
October 26, 2023: Expert Review of Vaccines
Ruyun Gao, Cuiling Zheng, Mengwei Yang, Liyuan Dai, Chen Chen, Jiarui Yao, Zhishang Zhang, Le Tang, Yuankai Shi, Xiaohong Han
BACKGROUND: Research on immunogenicity after 3rd SARS-CoV-2 vaccine in elder hepatocellular carcinoma (HCC) was limited. This study aimed to investigate the efficacy and influencing factors of inactivated SARS-CoV-2 vaccine in elder HCC. RESEARCH DESIGN AND METHODS: We assessed total antibodies, anti-RBD IgG, and neutralizing antibodies (NAb) toward SARS-CoV-2 wild type (WT) as well as BA.4/5 in 304 uninfected HCC, 147 matched healthy control (HC), and 53 SARS-CoV-2 infected HCC, all aged over 60 years...
October 25, 2023: Expert Review of Vaccines
Shiqi Zhou, Yuan Luo, Jonathan Lovell
INTRODUCTION: Liposomes have been used as carriers for vaccine adjuvants and antigens due to their inherent biocompatibility and versatility as delivery vehicles. Two vial admixture of protein antigens with liposome-formulated immunostimulatory adjuvants has become a broadly used clinical vaccine preparation approach. Compared to freely soluble antigens, liposome-associated forms can enhance antigen delivery to antigen-presenting cells and co-deliver antigens with adjuvants, leading to improved vaccine efficacy...
October 25, 2023: Expert Review of Vaccines
Yingping Chen, Xinpei Zhang, Lihui Gong, Zhenzhen Liang, Xiaosong Hu, Bo Xing, Yuting Liao, Lingfeng Yuan, Gang Chen, Huakun Lv
BACKGROUND: Because SARS-CoV-2 mutations and immunity wane over time, a third dose of heterologous COVID-19 vaccine is proposed for individuals primed with inactivated COVID-19 vaccine. RESEARCH DESIGN AND METHODS: We conducted a single-center, open-label trial to assess the safety, immunogenicity, and immune-persistence of a heterologous BBIBP-CorV/ZF2001 prime-boost vaccination in Chinese adults. 480 participants who had been primed with two doses of BBIBP-CorV, received a third dose of ZF2001 after an interval of 3-4, 5-6, or 7-9 months...
October 25, 2023: Expert Review of Vaccines
Timo Vesikari, Joanne M Langley, Vlad Popovic, Francisco Diaz-Mitoma
INTRODUCTION: Hepatitis B remains a major cause of death and morbidity worldwide. Universal childhood immunization programs have been very successful, but many adults remain unprotected or are not optimally protected. PreHevbrio [Hepatitis B Vaccine (recombinant)]is a highly immunogenic 3-antigen (S/pre-S1/pre-S2) hepatitis B vaccine (3A-HBV) that recently received marketing authorization in the United States (2021), the European Union, United Kingdom (2022 - brand name PreHevbri), and Canada (2022- brand name PreHevbrio) for the prevention of infection caused by all known subtypes of the hepatitis B virus and the delta virus in adults 18 years and older...
October 25, 2023: Expert Review of Vaccines
Sophie Marbaix, Annick Mignon, Audrey Taelman, Ahuva Averin, Mark Atwood, Jeffrey Vietri
BACKGROUND: The Belgian Superior Health Council (SHC) preferentially recommended the 20-valent pneumococcal conjugate vaccine (PCV20) for adults aged ≥65 years, immunocompromised patients, and patients aged ≥50 years suffering from conditions that increase their risk for pneumococcal infections. The objective of this paper is to present the cost-utility of PCV20 compared to no vaccination and the alternative sequence of PCV15 followed by the 23-valent pneumococcal polysaccharide vaccine (PPV23) in this population...
October 23, 2023: Expert Review of Vaccines
Irnela Bajrovic, Maria A Croyle
No abstract text is available yet for this article.
October 20, 2023: Expert Review of Vaccines
Yajie Gong, Xi Zhang, Xue Han, Baolan Chen, Yingxia Xu, Jitian Huang, Wenhan Yang, Xi Fu, Qiancui Wang, Zhongjun Li, Chunfeng Wu, Tianran Shen, Yuting Fan, Yingshi Dai, Yaping Qiao, Gang Zeng, Jikai Zhang, Qingsong Chen
BACKGROUND: As pregnant women are excluded from clinical trials of inactivated SARS-CoV-2 vaccines, it is important to assess the immune response in women receiving the vaccination while unknowingly pregnant. METHODS: In a multicenter cross-sectional study, we enrolled 873 pregnant women aged 18-45 years. Serum antibody levels induced by inactivated vaccines were determined. Adverse events were collected by self-reported survey after vaccination. Logistic regression model and restricted cubic spline model were used to investigate the association of factors with antibody positivity...
October 19, 2023: Expert Review of Vaccines
Jovin J Y Choo, Christopher L D McMillan, Paul R Young, David A Muller
INTRODUCTION: Microneedles are emerging as a promising technology for vaccine delivery, with numerous advantages over traditional needle and syringe methods. Preclinical studies have demonstrated the effectiveness of MAPs in inducing robust immune responses over traditional needle and syringe methods, with extensive studies using vaccines targeted against different pathogens in various animal models. Critically, the clinical trials have demonstrated safety, immunogenicity and patient acceptance for MAP-based vaccines against influenza, measles and rubella, and SARS-CoV-2...
October 17, 2023: Expert Review of Vaccines
Maria L Avila Agüero, Jose Brea Del Castillo, Luiza Helena Falleiros-Arlant, Eitan Berezín, Jose Cassio de Moraes, Carlos Torres-Martínez, Eduardo L Lopez, María E Castillo, Almudena Laris-Gonzalez, Fortino Solorzano, Angela Gentile, Juan Pablo Torres Torretti, Eduardo López-Medina
INTRODUCTION: The WHO 2030 Immunization Agenda (IA-2030) harmonizes immunization activity plans at community, national, regional and global levels. Additionally, medical societies play an important role. The Latin American Group of Experts on Infant Immunization, established in 2018, advises on the harmonization, update, and optimization of infant vaccination programs in Latin America and the Caribbean (LAC). In September 2021, 41 such experts from 13 LAC countries met to develop recommendations for increasing regional vaccination coverage to avoid the reemergence of vaccine-preventable diseases and/or the occurrence of outbreaks...
October 16, 2023: Expert Review of Vaccines
Peter D Skidmore, Rocio Canals, Maheshi N Ramasamy
No abstract text is available yet for this article.
October 12, 2023: Expert Review of Vaccines
María L Avila-Agüero, Sebastián Ospina-Henao, Cristina Mariño, Mirella Vázquez-Rivera, Juan Pablo Torres, Dora Estripeaut, Rolando Ulloa-Gutierrez, Angela Gentile
BACKGROUND: Pertussis remains as one of the oldest leading vaccine-preventable diseases of childhood, despite many decades of primary vaccine doses and boosters' implementation. Although the epidemiology is well understood in infants and children, premature babies and low-birth weight infants remain a special group where the disease incidence is unknown, severity of the disease is considerable, and specific vaccination recommendations are scarce. RESEARCH DESIGN AND METHODS: Retrospective review of the available evidence of pertussis vaccination in premature and low birth weight infants was analyzed from January 2000 to December 2022 in six selected countries: Argentina, Mexico, Colombia, Panamá, Costa Rica, and Chile...
October 10, 2023: Expert Review of Vaccines
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.